id: copd_appropriate_medication_use_to_abstinence_promotion
name: COPD Appropriate Medication Use â†’ Promotion of Alcohol Abstinence
from_node:
  node_id: copd_appropriate_medication_use
  node_name: COPD Appropriate Medication Use
  _original_id: fda_approved_aud_medications
to_node:
  node_id: abstinence_promotion
  node_name: Promotion of Alcohol Abstinence
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: FDA-approved medications (disulfiram, oral naltrexone, acamprosate, extended-release
  naltrexone) target major neurotransmitter systems affected by chronic heavy alcohol
  use'
- 'Step 2: Medications modulate neurobiological pathways involved in craving, reinforcement,
  and withdrawal symptoms'
- 'Step 3: Neurochemical normalization and symptom reduction support individuals in
  maintaining abstinence'
- 'Step 4: Consistent medication access and adherence leads to sustained abstinence
  or reduced alcohol consumption'
evidence:
  quality_rating: B
  n_studies: 4
  primary_citation: 'Henry R Kranzler and Emily E Hartwell 2023. "Medications for
    treating alcohol use disorder: A narrative review.." *Alcohol, clinical & experimental
    research*. https://doi.org/10.1111/acer.15118'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.670985'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: clinical_practice_implementation
  direction: strengthens
  strength: strong
  description: Evidence-based medications are underutilized in clinical practice,
    indicating that implementation factors moderate actual treatment effects at population
    level
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/healthcare_access/fda_approved_aud_medications_to_abstinence_promotion.yaml
_category: healthcare_access
